KNE Kane Biotech Inc.

TSXV · CA · Healthcare · Biotechnology · kanebiotech.com

0.0300CAD0.00%Mkt Cap: 4.48M $P/E: —4d ago

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company d…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap4.48M USD

Enterprise Value5.29M USD

Revenue (TTM)28.20K USD

Gross Profit-466 USD

Net Income (TTM)-1.98M USD

Revenue/Share0.00 CAD

Last Price0.0300 CAD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-2.76

EV/Revenue187.50

P/S158.88

P/B-6.00

EPS (TTM)-0.02

EPS (Forward)—

52W Range

0.015043% of range0.0500

52W High0.0500 CAD

52W Low0.0150 CAD

Profitability

Gross Margin-0.15%

Oper. Margin-9633.83%

EBITDA Margin0.00%

Profit Margin-636.00%

ROE364.51%

ROA-99.53%

Growth

Revenue Growth-70.90%

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.37M USD

CapEx (TTM)82.39K USD

FCF Margin-4431.31%

FCF Yield-27.89%

Net Debt807.16K USD

Net Debt/EBITDA-0.42

Balance Sheet

Debt/Equity-3.09

Current Ratio0.61

Quick Ratio0.35

Book Value/Sh-0.0050 CAD

Cash/Share0.0040 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay DateMar 13, 2017

Splits

Last Split1:5

Split DateMar 13, 2017

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.205.06M

Float105.14M

Insiders39.82%

Institutions0.00%

Short Interest

Short Ratio0.2d

Short % Out.0.00%

Shares Short6.84K

Short (prev mo.)9.09K

Technical

SMA 500.0294 (+2.0%)

SMA 2000.0347 (-13.5%)

Beta0.31

S&P 52W Chg14.58%

Avg Vol (30d)155.34K

Avg Vol (10d)21.91K

Technical Indicators

RSI (14)53.4

MACD0.0002

MACD Signal0.0001

MACD Hist.+0.0001

BB Upper0.0343 CAD

BB Middle0.0288 CAD

BB Lower0.0232 CAD

BB Width38.27%

ATR (14)0.0026 CAD

Vol Ratio (20d)0.10x